Influence Of COVID19 Vaccines On Diabetes Management

Mohammad Abuzaid[1*] , Waleed Badawyeh[1]

Primary health care corporation (PHCC), Muaither health Center, Doha, Qatar.

Mabuzaid@phcc.gov.qa[*], Wbadawyeh@phcc.gov.qa

Correspondent email[*]: Mabuzaid@phcc.gov.qa

Abstract

The availability of different vaccines plays a crucial role in bringing the COVID-19 pandemic to a standstill. All the vaccines with two initial and a booster dose have reduced the mortality rate and do not elicit serious symptoms or illness. However, the clinical trials on different vulnerable populations are still not reliable. In particular, COVID-19 patients belonging to the diabetic population exhibited higher morbidity and mortality. Therefore, the prioritization of vaccination for these populations may reduce further complications. Yet, the hesitancy toward vaccines hinders the process of vaccination campaigns. Hence, this review focuses on the availability of different vaccines against COVID-19 and their role in eradicating previous epidemics. The effect of this vaccination on the diabetic group and the management of chronic illness have been emphasized.

Introduction

Later in 2019, a unique kind of coronavirus, currently being called SARSCoV-2, was found to cause a severe acute respiratory illness outbreak in Wuhan, a city located in China's main region. The WHO also recognized it as COVID-19 and as coronavirus disease in February 2020. This infection can cause different complications, starting from asymptomatic to acute pneumonia, including critical respiratory distress illness, septic shock, and failure of many organs simultaneously [1]. It is noteworthy that all the diseases mentioned above can lead to death. It was announced as an emergency for public health that raised concern worldwide. In addition, it labeled it a pandemic in March 2020 to announce and stress the emergency of the situation. It advised all governments worldwide to take measures to identify and remedy the infection. This particular virus that causes COVID-19 is reported to have the ability to advance from one human to another human, majorly by the droplets from the respiration that occurs when a person with infection sneezes or coughs. These aerosols then reach and land on the nose or mouth part of a person who stands in the surroundings. Sometimes, they are even inhaled and reach the lungs. Other transmission routes are reported, such as inhalation of aerosols produced when generating the procedures or being in contact with the contaminated fomites.

The world has witnessed three waves of the coronavirus till now, and more are expected in the future, whereas several challenges are present [2]. Besides the terrible death toll, many people are affected by the long-term effects of a severe acute respiratory disorder coronavirus two diseases; others, even minor COVID-19, can be disastrous for weeks when medically cured [3, 4]. The second wave pertains to people who have suffered in the medium term due to COVID-19 prevention strategies. It includes, in addition to the multiple factors, those who abstain from their regular medical check-ups in the view and fear of contracting the infection from the infected patients, the people who were seriously affected with the other types of deadly disease, who postponed their regular medical check-up’s and skipped screening. In the third wave, the major concern is the impact of the virus on psychosocial factors and its consequences in the long term. This virus has aggravated and caused significant harm around the world.

The conventional practice for constraining the s of instances is to stay vigilant. Early detection, diagnosing, containment, and medication are required to avoid future transmission. Individuals are isolated, and infection control is closely monitored, with necessary actions to be taken during assessment and the administration of healthcare to a person infected [5]. One of the most crucial techniques for the public to follow is to wash their hands repeatedly, use transportable antibacterial wipes, and avoid touching their face or mouth after coming into contact with potential contamination. Individuals should be urged to clean their hands frequently, maintain respiratory hygiene (i.e., cover their coughing), and make reservations and frequent connections with unwell people as much as possible to limit the risk of transmission in the community [6, 7]. Many companies have introduced posters and pamphlets on all aspects of COVID-19 protection, which are extensively distributed worldwide [8]. The World Health Organization (WHO) and other related health agencies have created visual aids such as documentaries and posters to educate about good personal hygiene. These posters, which were circulated throughout the community to promote awareness about the need for hand cleanliness, raised the awareness in almost all of them. The pandemic was kept under control even more rapidly as the number of people carrying antibacterial wipes for instant hand cleanliness and the expansion of mask adoption among individuals in nations such as China, Japan, and Thailand increased. The enormous spike in incidents persists in countries where such precautions are not mandated. Disassociating yourself from others is recommended, especially in areas with community propagation. Several countries have implemented isolation and social/physical separation measures to prevent the virus from spreading further.

These measures could include the suspension of public universities and enterprises entirely or partially, such as restricting the number of visits and the amount of contact between inhabitants of constrained settings like long-term care facilities and jails is a good idea. Termination, banning, limitation of public events and smaller gatherings, obligatory decontamination of institutions or residential neighborhoods', internal or external border closures, and stay-at-home prohibitions for entire regions are all possibilities.

Vaccine and History

Among the most significant scientific achievements of the twenty-first century has been the discovery of safe and effective vaccines against illnesses that cause serious health consequences. Vaccination is a global health policy with hygiene and clean water that has unquestionably enhanced global healthcare outcomes. Vaccines are thought to have avoided millions of deaths from immunization preventable diseases every year. The world's population is expected to reach about 10 billion by 2055, made possible in part by vaccination programs that prevent respiratory symptoms and extend life spans across all regions.

Since 1500 AD, humans have used treatments to prevent certain diseases, starting in China, wherein smallpox was controlled by variolation or the insertion of substance from the crustiest into the epidermis. Edward Jenner detected protection against chickenpox in milkmaids who had already been naturally infected with cowpox in the United Kingdom in 1796 [9]. He discovered that injecting minimal quantities of pus from live virus sores into intermediate hosts, presumably carrying a virus similar to vaccinia, made them resistant to chickenpox. In 1798, the smallpox vaccine was produced.

It required nearly a century of investigation to produce the next stage of new advances, which involved manipulating bacterial infections to obtain acceptable vaccination antigens. At the beginning of the millennium, Louis Pasteur's experiments with attrition by air or heat resulted in live-attenuated chicken cholera, inactivated anthrax, and live-attenuated rabies vaccinations [10]. Different attenuation procedures, including the esteem and confidence of Mycobacterium Bovis, resulted in the live Bacille Calmette-Guerin (BCG) vaccine, which is still used to prevent disease today [11]. Yellow fever vaccines produced in chicken embryo fibroblasts have also been developed using the serial transmission. When ways of treating and killing germs with heat or chemicals were discovered, whole-cell typhus, hepatitis, and diphtheria vaccines got introduced.

The close of the twentieth century saw a revolution in molecular genetics, which led to new insights into bacteriology and immunotherapy, leading to a better understanding of pathogen epitopes and vaccine responses. Genetic testing and functional genomics have allowed vaccines to be developed to target RNA viruses with various epitope variations, such as live and downregulated influenza vaccines and live rotavirus vaccinations [12]. The surface epitope for hepatitis B bacteriophages was made possible by DNA modification and excision. Due to the production of virus-like particles by the L1 antigen of each virus present in the vaccination, the papillomavirus (HPV) vaccine has improved immunogenicity. Meningococcal antigens have been thoroughly examined using bacterial genotyping to find promising proteins for pneumococcal B vaccines.

The health benefits of vaccination include eradicating deaths and reducing mortality rates, eliminating deadly diseases, developing a herd immunity among the communities, preventing secondary diseases that evolve from a particular primary disease, preventing cancer, and preventing antibiotic resistance. When a novel coronavirus, SARS-CoV-2, surfaced from China in 2020, producing a deadly acute respiratory sickness that spread internationally, vaccine production was tested. Within 5 days of the virus's detection and person-to-person dissemination, around 5,697,335 cases had already been recorded, with factors of magnitude presumably not recorded, and nearly no nation had survived the epidemic. Without documenting the public health initiative that led to the widespread use of these vaccinations for children worldwide, the chronology of immunization would be incomplete. WHO established the Expanded Program of Immunization (EPI) in 1974 to give routine vaccinations to all adolescents by 1990 [13].

Different COVID19 Vaccines across the globe

The importance of timely and proper immunization in diseases' basic prevention and treatment cannot be overstated. The following is a list of the various types of vaccines produced around the world:

BNT162b2, a type of Lipid nanoparticle formulation, nucleotide mRNA vaccine encodes a prefusion stabilized, membrane-anchored SARSCoV-2 spike glycoprotein was manufactured by Pfizer-BioNTech USA, Germany and has passed through the 2/3 trial phase and shows the efficacy of 95% [15]. Similarly, the Sputnik V vaccine (Gam COVID-Vac) is a Combined vector vaccine based on recombinant adenovirus (rAd) type 26 and rAd type 5d, both of which carry the gene for SARS-CoV-2 spike glycoprotein manufactured by Gamaleya Research Institute of Epidemiology and Microbiology Russia shows the efficacy of 3% passing through the third phase of the trials. The vaccine named mRNA-1273 produced by the Moderna and the Vaccine Research Centre at NIAID USA has made its way through the third trial. It shows the efficacy of 94.1 % in a Lipid-nanoparticle encapsulated mRNA vaccine expressing the prefusion-stabilized SARSCoV-2 spike glycoprotein type of drug [16]. In India, COVAXIN™ and COVISHIELD™ have been approved by the Drug Controller General of India (DCGI) for restricted use in an emergency.JNJ-78436735 or Ad26.COV2.S, a Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein type of drug, shows 66% efficacy and is being manufactured by Johnson & Johnson (Janssen Biotech, Inc.) the USA. Novavax, Inc. USA has manufactured a drug named NVX-CoV2373, a Matrix-M1 adjuvant and recombinant SARS-CoV-2 nanoparticle vaccine constructed from the full-length, wild-type SARS-CoV-2 spike glycoprotein type drug shows the efficacy of 89%. It has cleared phase three of the trials. A Recombinant, replication-deficient chimpanzee adenoviral vector ChAdOx1, containing the SARS-CoV-2 spike glycoprotein antigen type of drug exhibiting 70.4% efficacy has cleared 1/2/3 of the trial phase, is named AZD1222 (ChAdOx1) and is being manufactured by the Oxford-AstraZeneca Jenner Institute, University of Oxford England.

The safety and effectiveness of the vaccination have been found to range from 56 percent to 81 percent in numerous case reports. The WHO's Strategic Advisory Group of Experts on Immunization (SAGE) has suggested using the Oxford-AstraZeneca vaccine (AZD1222) in patients with comorbidities that were linked to a higher risk of severe COVID-19 infection [17]. Hypertension, coronary heart disease, pulmonary disease, and hypertension were among the comorbidities evaluated in the drug testing. By the Advisory Committee on Immunization Practices (ACIP) recommendations, the Centre for Disease Control and Prevention (CDC) has advised that the early quantities of the COVID-19 vaccine be given to healthcare staff and long-term treatment facility patients. Phase 1a is the name given to this stage. Vaccination will be offered as part of Phase 1b and Phase 1c. People aged 16 and older who have pre-existing medical problems that enhance the likelihood of major, life-threatening COVID-19 consequences are included in Phase 1c.

COVID19 Vaccine complications and comorbidity

Immunomodulatory therapy patients are particularly vulnerable to Covid19-related incidence and death. While it ought to be a top concern for health practitioners and governments to vaccinate these communities, they have been largely omitted from vaccination trials [18]. The main rationale for these restrictions is that immunosuppression medications can impede immunization of humoral and cellular immune reactions, making it impossible to assess the drug's body's immune efficiency. It's worth noting that there is a slew of these disorders, none of which have a fully understood pathophysiology. As a result, when evaluating vaccination, it's critical to think about the illnesses and how they're treated.

Corticosteroids have a daily dosage effect on immunization antibodies synthesis [19]. Fludrocortisone doses greater than 10 mg per day, or equal levels of other corticosteroids, reduce vaccine responsiveness; therefore, reducing the dose at vaccination point begins to be important. Disease-modifying antirheumatic medicines are medications that relieve pain in inflammatory conditions.

TNF inhibitors, including TCZ, ABA, and IL17 inhibitors, appear to affect vaccine efficacy negatively. The Centres for Disease Prevention and Control (CDC) advises that these agents be given at least 2 weeks apart from vaccination. As a result, the decision to vaccinate patients with underlying patients who take the following drugs must be individualized, as low-dose immunosuppressive treatments seem to have little effect on the vaccine-induced neutralizing antibodies. Ultimately, it is better to protect these individuals once their underlying condition has been managed. It's also worth noting that allergy symptoms can occur after immunization in these individuals, particularly those with inflammatory arthritis, requiring a prolonged observation time (at least 2 hours) after vaccination [20].

Another crucial factor to examine is the product's safety profile. In rheumatic individuals, Covid19 vaccinations do not appear to be effective. Neither of the medications reduces vaccinations; hence they are prohibited. Nevertheless, it is still unclear if Covid19 vaccinations can cause autoimmune by engaging the immune function comprehensively or directly. Adjuvant actions result in worsening rheumatologic or other diseases and inflammatory conditions. Such outcomes could occur as a result of the Pfizer/BioNTech deal.

Nevertheless, the advantages of vaccination outweigh the risks. The hazard of aggravating autoimmune disease outweighs the risk for disadvantaged people. The American College of Rheumatology advises the following treatments for rheumatoid arthritis: all suitable rheumatologic patients should be vaccinated with Covid19 [21]. Some speculate that vaccination analysis of protein subunits, including the vaccine option Novavax, will be more productive and useful for rheumatologic, autoimmune, and autoinflammatory illnesses [22].

Vaccine hesitancy

Vaccination is now underway in several nations throughout the world. Despite this, many continue to have concerns about vaccination safety and effectiveness and the lifetime of COVID-19 immunity, while several cases of contracting the disease have been documented. Furthermore, the fast development of immunotherapies raises concerns about their safety. Vaccine preparation has already been connected to negative consequences. The swine flu vaccine, for instance, raised fears of Guillain-Barré illness. However, the WHO has grown the awareness of the benefits of vaccination in eradicating the COVID19, and the efficacy results appear to be positive in eliminating the outbreak [23].

Diabetes Mellitus

Diabetes is a collection of metabolic illnesses marked by hyperglycemia caused by insulin production, hyperinsulinemia, or both. The relevance of glucagon as a proliferative enzyme causes metabolic irregularities in carbohydrates, triglycerides, and peptides. These physiologic abnormalities are caused by low hyperinsulinemia to achieve a solid solution and insulin inhibition of peripheral tissue, primarily skeletal muscles, adipocytes, and to a smaller degree, liver, at the stage of insulin receptors, signaling pathways scheme, and signal transduction amylases or genes. The kind and presence of disease assess the severity of symptoms. Type 1, type 2, and other forms such as gestational diabetes mellitus (GDM) have always been the most widely acknowledged and approved classifications of diabetes, as presented either by American Diabetes Association (ADA) in 1997.

D.M. management during pandemics

Diabetes was common in individuals hospitalized with COVID19 initially during the epidemic. Diabetes, like high blood pressure, is among the most common symptoms in Corsica, Europe, and New York, United States. Diabetic patients are more prone to Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) infection, according to past studies, due to a dysfunctional immune reaction that results in severe and widespread lung damage. As a result, it's not unexpected that this demographic is at a higher risk of contracting COVID-19 disease.



Figure 1. Schematic illustration of the influence of D.M. in COVI19 mortality [24].

Numerous biochemical pathomechanisms, as mentioned below, may make diabetic people sensitive to COVID-19. To begin, hyperglycemia was linked to poorer phagocytic activity, neutrophil chemotaxis, T cell performance, and overall adaptive immune resistance [25]. Numerous biochemical pathomechanisms, as mentioned below, may make diabetic people sensitive to COVID-19. For starters, hyperglycemia was linked to reducing granulocytes, neutrophil chemotaxis, T cell activity, and overall innate immune system resistance. People who have diabetes also showed increasing amounts of insulin-like growth factor enzyme-2 (ACE2) than the general population. Because of its strong affinity attachment, ACE2 serves as an entry binding site for SARS-CoV-2, and it is identified in human respiratory system alveolar cells, cardiomyocytes, interstitium, and other tissues [26]. As a result, SARS-CoV-2 has a strong attraction for intracellular attachment and viral entrance, resulting in reduced primary infection. Finally, increased glucose levels directly promote SARSCoV-2 proliferation, with potentially deadly consequences owing to innate immunity and systemic inflammation abnormalities. This mechanism has been successfully proven in mononuclear cells, wherein increased glucose levels and glycolysis regulate mitochondrial oxygen radicals generation and activate hypoxia-inducible factor 1, which promotes tumorigenesis. Finally, there could be a link between glucose deficiency and naturally killer (N.K.) cell activation in cytotoxic lymphocytes. HbA1c levels are an important risk factor for N.K. Cell activity, according to a generalized linear study. Those with pre-existing T2dm (Type 2 diabetes mellitus) and hypertension have decreased N.K. Cellular activities than individuals without T2DM.

To the best of our knowledge, given the perceived hazard, there is no good factual information showing increased sensitivity to SARS-CoV-2 infection in individuals with diabetes. Diabetes has indeed been implicated in the development of poor COVID-19 illness consequences, such as the development of acute respiratory distress syndrome (ARDS) and death, since the beginning of the epidemic [27]. However, while early, initial reports from the many randomized trials had poor quality on average due to the focus on speed, which compromised essential epidemiology basics. As a result, a better comprehension of diabetes, other pathologies, and their influence on COVID-19 are impossible. We've covered conceptual and a few key epidemiological research that has aided our understanding of D.M. and COVID-19. In a conceptual analysis comprising 30 trials and 6451 hospitalized COVID-19 patients, others with D.M. had twofold greater rates of death and disease characteristics. Subject replication and recurrent analysis were key limitations of this contextual analysis, leading to unreliable results in one-third of non-survivors in a significant population study in Britain involving 61,414,472 people. In a comprehensive survey, the probabilities for in-hospital fatality were 2.86 for type 1 diabetes and 2.15 for type-2 diabetes compared to non-equivalents. Nonetheless, because latent variables (smoking history, BMI, and inadequate cardiovascular morbidities) were not handled by the approach, these conclusions are constrained.

In England, an inhabitants' cohort research discovered numerous risk variables related to death in T1DM and T2DM patients due to COVID-19. In addition to some well-known health conditions, diabetes control (HbA1C) and BMI were independently associated with the main measure, COVID-19 associated death, using a nationwide dataset of diabetic patients enrolled in clinical practitioners. In this other large cohort study covering all Scottish communities, individuals with Type 1 diabetes and Type 2 diabetes mellitus had substantially greater odds of dying or essential care administered by COVID-19 than those with less, and after gender and age correction, with O.R.s of 2.40 and 2.40, respectively, in this other large cohort study covering all Scottish communities. Quite pertinently, this study found that people who smoke were more likely to develop consequences among diabetes patients, particularly those with much more serious Type 2 diabetes mellitus and those who reside in residential care homes or disadvantaged neighborhoods), which managed to stay significant after adjusting for demographic, gender, diabetes type, and timeframe.

And in the meantime, the COVID-19 hospital visit in the England Surveillance Network found that COVID-19 patients with T2DM hospitalized in the crucial context (had a 23 percent elevated incidence of all-cause fatalities aHR of 1.22, which was lesser than the studies mentioned above. More crucially, this study revealed that among diabetic patients, those with more serious D.M. in combination have a higher risk of death. France is the source of big research on D.M. in COVID-19.

The COVID-19 SARS-CoV-2 and Diabetes Outcomes research involved 68 French institutions and aimed to define phenotypically hospitalized patients with D.M. and COVID-19. This research yielded several significant findings. BMI was the only pre-admission predictor linked to the primary endpoint, a combination of tracheostomy and mortality within seven days of admission. Secondly, during admission, numerous laboratory tests, including lymphocytosis, c-reactive protein expression (CRP), and aspartate aminotransferase, were linked to the outcome measure (AST). Diabetes-related micro and cerebrovascular disease problems were related to increased mortality risk. Long-term glucose management (HbA1C levels) was unexpectedly unrelated to the primary outcome.

Before the epidemic, there would be a lack of mass acceptance of health-related technologies—advancements in diabetes management, with pediatrics' taking the lead in the competition.

However, the COVID-19 epidemic has changed how we care for our patients. In a particular instance, integrating telehealth surveillance and CGM improved systems considerably, necessitating the early implementation of both techniques.

Diabetic individuals can now be treated as outpatients. Due to telehealth, individuals with type 1 diabetes mellitus now have more access to physicians. Simultaneously, the videoconferencing system and the patient's blood pressure statistics collected by the clinicians could handle T1D more effectively thanks to telemedicine.

Additionally, prioritizing vaccination for the diabetic population may prove significantly beneficial by curbing the mortality rates and thus managing the diabetic patients during the epidemic.

Conclusion

We have summarized the importance of vaccines in previous pandemics and COVID19. This review also highlighted the vulnerability of the diabetic population to COVID19 and emphasized the trade-off between prioritizing vaccination and vaccination hesitancy. We have also demonstrated the research gap in identifying the complications of vaccines in the diabetic population.

References

[1] Chong, W.H., Saha, B.K., 2021. Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). The American Journal of the Medical Sciences 361, 287–296. https://doi.org/10.1016/j.amjms.2020.10.025

[2] Lai, J.W., Cheong, K.H., 2020. Superposition of COVID-19 waves, anticipating a sustained wave, and lessons for the future. BioEssays 42, 2000178. https://doi.org/10.1002/bies.202000178

[3] De Felice, F.G., Tovar-Moll, F., Moll, J., Munoz, D.P., Ferreira, S.T., 2020. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System. Trends in Neurosciences 43, 355–357. https://doi.org/10.1016/j.tins.2020.04.004

[4] Fernández-de-las-Peñas, C., Rodríguez-Jiménez, J., Fuensalida-Novo, S., Palacios-Ceña, M., Gómez-Mayordomo, V., Florencio, L.L., Hernández-Barrera, V., Arendt-Nielsen, L., 2021. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Pain 162, 2832–2840. https://doi.org/10.1097/j.pain.0000000000002306

[5] Bielicki, J.A., Duval, X., Gobat, N., Goossens, H., Koopmans, M., Tacconelli, E., van der Werf, S., 2020. Monitoring approaches for healthcare workers during the COVID-19 pandemic. The Lancet Infectious Diseases 20, e261–e267. https://doi.org/10.1016/S1473-3099(20)30458-8

[6] Nicola, M., O'Neill, N., Sohrabi, C., Khan, M., Agha, M., Agha, R., 2020. Evidence-based management guideline for the COVID-19 pandemic - Review article. International Journal of Surgery 77, 206–216. https://doi.org/10.1016/j.ijsu.2020.04.001

[7] Magiorakos, A.P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U., Lucet, J.C., Moro, M.L., Tacconelli, E., Simonsen, G.S., Szilágyi, E., Voss, A., Weber, J.T., 2017. Infection prevention and control measures and tools for preventing entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control 6, 113. https://doi.org/10.1186/s13756-017-0259-z

[8] Pan, L., Wang, J., Wang, X., Ji, J.S., Ye, D., Shen, J., Li, L., Liu, H., Zhang, L., Shi, X., Wang, L., 2022. Prevention and control of coronavirus disease 2019 (COVID-19) in public places. Environmental Pollution 292, 118273. https://doi.org/10.1016/j.envpol.2021.118273

[9] Weiss, R.A., Esparza, J., 2015. The prevention and eradication of smallpox: a commentary on Sloane (1755) 'An account of inoculation.' Phil. Trans. R. Soc. B 370, 20140378. https://doi.org/10.1098/rstb.2014.0378

[10] D'Amelio, E., Salemi, S., D'Amelio, R., 2016. Anti-Infectious Human Vaccination in Historical Perspective. International Reviews of Immunology 35, 260–290. https://doi.org/10.3109/08830185.2015.1082177

[11] Rajarshi, K., Chatterjee, A., Ray, S., 2020. BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope? Medicine in Drug Discovery 7, 100049. https://doi.org/10.1016/j.medidd.2020.100049

[12] Katze, M.G., Fornek, J.L., Palermo, R.E., Walters, K.-A., Korth, M.J., 2008. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol 8, 644–654. https://doi.org/10.1038/nri2377

[13] Levine, O.S., Bloom, D.E., Cherian, T., de Quadros, C., Sow, S., Wecker, J., Duclos, P., Greenwood, B., 2011. The future of immunization policy, implementation, and financing. The Lancet 378, 439–448. https://doi.org/10.1016/S0140-6736(11)60406-6

[14] Pal, R., Bhadada, S.K., Misra, A., 2021. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15, 505–508. https://doi.org/10.1016/j.dsx.2021.02.026

[15] Jones, I., Roy, P., 2021. Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet 397, 642–643. https://doi.org/10.1016/S0140-6736(21)00191-4

[16] Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B.S., Bennett, H., Pajon,

R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., Zaks, T., 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416. https://doi.org/10.1056/NEJMoa2035389

[17] Whitaker, H.J., Tsang, R.S.M., Byford, R., Andrews, N.J., Sherlock, J., Sebastian Pillai, P., Williams, J., Button, E., Campbell, H., Sinnathamby, M., Victor, W., Anand, S., Linley, E., Hewson, J., DArchangelo, S., Otter, A.D., Ellis, J., Hobbs, R.F.D., Howsam, G., Zambon, M., Ramsay, M., Brown, K.E., de Lusignan, S., Amirthalingam, G., Lopez Bernal, J., 2022. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection S0163445321006642. https://doi.org/10.1016/j.jinf.2021.12.044

[18] Mohseni Afshar, Z., Babazadeh, A., Janbakhsh, A., Mansouri, F., Sio, T.T., Cullman, M.J.M., Carson-Chahhoud, K., Hosseinzadeh, R., Barry, M., Ebrahimpour, S., 2021. Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. Rev Med Virol. https://doi.org/10.1002/rmv.2309

[19] Annane, D., 2021. Corticosteroids for COVID-19. Journal of Intensive Medicine 1, 14–25. https://doi.org/10.1016/j.jointm.2021.01.002

[20] Ishay, Y., Kenig, A., Tsemach-Toren, T., Amer, R., Rubin, L., Hershkovitz, Y., Kharouf, F., 2021. Autoimmune phenomena following SARS-CoV-2 vaccination. International Immunopharmacology 99, 107970. https://doi.org/10.1016/j.intimp.2021.107970

[21] Curtis, J.R., Johnson, S.R., Anthony, D.D., Arasaratnam, R.J., Baden, L.R., Bass, A.R., Calabrese, C., Gravallese, E.M., Harpaz, R., Kroger, A., Sadun, R.E., Turner, A.S., Williams, E.A., Mikuls, T.R., 2021. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis & Rheumatology 73. https://doi.org/10.1002/art.41928

[22] Velikova, T., Georgiev, T., 2021. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 41, 509–518. https://doi.org/10.1007/s00296-021-04792-9

[23] Al-Qerem, W.A., Jarab, A.S., 2021. COVID-19 Vaccination Acceptance and Its Associated Factors Among a Middle Eastern Population. Front. Public Health 9, 632914. https://doi.org/10.3389/fpubh.2021.632914

[24] Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., Li, Haomiao, Zhang, P., Song, X., Chen, X., Xiang, M., Zhang, Chaozheng, Bai, L., Xiang, D., Chen, M.-M., Liu, Y., Yan, Y., Liu, M., Mao, W., Zou, J., Liu, L., Chen, G., Luo, P., Xiao, B., Zhang, Changjiang, Zhang, Z., Lu, Z., Wang, J., Lu, H., Xia, X., Wang, D., Liao, X., Peng, G., Ye, P., Yang, J., Yuan, Y., Huang, X., Guo, J., Zhang, B.-H., Li, Hongliang, 2020. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and

Pre-existing Type 2 Diabetes. Cell Metabolism 31, 1068-1077.e3. https://doi.org/10.1016/j.cmet.2020.04.021

[25] De Bandt, J.-P., Monin, C., 2021. Obesity, Nutrients and the Immune System in the Era of COVID-19. Nutrients 13, 610. https://doi.org/10.3390/nu13020610

[26] Beyerstedt, S., Casaro, E.B., Rangel, É.B., 2021. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 40, 905–919. https://doi.org/10.1007/s10096-020-04138-6

[27] Calabrese, E.J., Kozumbo, W.J., Kapoor, R., Dhawan, G., Lara, P.C., Giordano, J., 2021. Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations. Radiotherapy and Oncology 160, 125–131. https://doi.org/10.1016/j.radonc.2021.04.015